Abstract：
BACKGROUND: Frontal fibrosing alopecia (FFA) is a cicatricial alopecia with rapid epidemic growth. However, there is no agreement on the best therapeutic approach.
OBJECTIVE: To compare the therapeutic effects of finasteride as a first-line systemic treatment of FFA versus hydroxychloroquine as a relatively safe and effective immunosuppressive drug.
METHODS: Thirty-four female FFA patients were randomly assigned to receive either 400 mg/day of hydroxychloroquine or 2.5 mg/day of finasteride for 6 months. Topical treatments in both groups include pimecrolimus, mometasone, and minoxidil. Treatment efficacy was evaluated using the Frontal Fibrosing Alopecia Severity Score (FFASS), photography, and trichoscopy after 3 and 6 months.
RESULTS: Both the finasteride and hydroxychloroquine groups showed significant improvements in FFASS and trichoscopic scores (p < 0.01). However, there was no significant difference between the two groups during the study. Photographic assessment showed that more than 60% of patients in both groups had improved without statistically significant differences between the two groups.
CONCLUSIONS: Both finasteride and hydroxychloroquine are equally effective, safe, and well-tolerable for treating FFA patients.
OBJECTIVE: To compare the therapeutic effects of finasteride as a first-line systemic treatment of FFA versus hydroxychloroquine as a relatively safe and effective immunosuppressive drug.
METHODS: Thirty-four female FFA patients were randomly assigned to receive either 400 mg/day of hydroxychloroquine or 2.5 mg/day of finasteride for 6 months. Topical treatments in both groups include pimecrolimus, mometasone, and minoxidil. Treatment efficacy was evaluated using the Frontal Fibrosing Alopecia Severity Score (FFASS), photography, and trichoscopy after 3 and 6 months.
RESULTS: Both the finasteride and hydroxychloroquine groups showed significant improvements in FFASS and trichoscopic scores (p < 0.01). However, there was no significant difference between the two groups during the study. Photographic assessment showed that more than 60% of patients in both groups had improved without statistically significant differences between the two groups.
CONCLUSIONS: Both finasteride and hydroxychloroquine are equally effective, safe, and well-tolerable for treating FFA patients.
摘要：
背景：额叶纤维性脱发（FFA）是一种迅速流行的瘢痕性脱发。然而,对最佳治疗方法没有达成一致。
目的：比较非那雄胺作为FFA的一线全身治疗与羟氯喹作为相对安全有效的免疫抑制药物的治疗效果。
方法：34名女性FFA患者被随机分配接受400mg/天羟氯喹或2.5mg/天的非那雄胺治疗6个月。两组的局部治疗包括吡美莫司，莫米松,还有米诺地尔.使用额叶纤维性脱发严重程度评分（FFASS）评估治疗效果，摄影,并在3个月和6个月后进行内窥镜检查。
结果：非那雄胺和羟氯喹组均显示出FFASS和镜下评分的显着改善（p<0.01）。然而,研究期间两组间无显著差异.摄影评估显示，两组中超过60％的患者均有所改善，两组之间无统计学差异。
结论：非那雄胺和羟氯喹都同样有效，安全,并且对FFA患者的治疗具有良好的耐受性。
目的：比较非那雄胺作为FFA的一线全身治疗与羟氯喹作为相对安全有效的免疫抑制药物的治疗效果。
方法：34名女性FFA患者被随机分配接受400mg/天羟氯喹或2.5mg/天的非那雄胺治疗6个月。两组的局部治疗包括吡美莫司，莫米松,还有米诺地尔.使用额叶纤维性脱发严重程度评分（FFASS）评估治疗效果，摄影,并在3个月和6个月后进行内窥镜检查。
结果：非那雄胺和羟氯喹组均显示出FFASS和镜下评分的显着改善（p<0.01）。然而,研究期间两组间无显著差异.摄影评估显示，两组中超过60％的患者均有所改善，两组之间无统计学差异。
结论：非那雄胺和羟氯喹都同样有效，安全,并且对FFA患者的治疗具有良好的耐受性。
